Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)

MDSC, CSC and the clusters in blood from NSCLC patients will be assessed to evaluate the impact of G-CSF on their phenotype and functions. Samples from 2 groups of NSCLC patients receiving chemotherapy and immunotherapy will be used: 15 receiving concomitant G-CSF, and 15 not receiving concomitant G-CSF

Inclusion criteria

• Patients (male or female) aged ≥ 18 years
• Histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy
• Receiving chemotherapy and immunotherapy as first-line treatment
• Signed written informed consent (no later than the day of inclusion, and before the blood sample collection)
• Patient affiliated or beneficiary to a health security system;

Exclusion criteria

• Patient with a small cell lung carcinoma
• Non-metastatic disease
• Actionable mutation or genomic alteration in EGFR, ALK or ROS1
• Corticosteroids > 10 mg/j
• Autoimmune disease
• Active and uncontrolled HIV infection
• Concomitant cancer
• Pregnancy or lactating women
• Psychiatric or medical conditions that prohibit the understanding and rendering of informed consent
• Patient under a legal protection measure
• Patient with a deprived liberty condition
• Patient incapable of giving signed informed consent
• Patient within the exclusion period for another clinical trial, or participating to another interventional trial within 30 days before the beginning of this project